Vb 111 Vbl Therapeutics Emerging Drug Insight And Market Forecast

“VB 111 (VBL Therapeutics)- Emerging Drug Insight and Market Forecast – 2030” the report provides comprehensive insights about an investigational product for Glioblastoma in 7 Major Markets. A detailed picture of the VB 111 (VBL THERAPEUTICS) in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2020–2030 is provided in this report along with a detailed description of the product. The product details cover mechanism of action, dosage and administration, route of synthesis, and Research and development activity including regulatory milestones, and other development activities. Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.

Drug Summary

Ofranergene obadenovec is a unique biologic agent that uses a dual mechanism to target solid tumors. Based on a non-integrating, non-replicating, Adeno 5 vector, ofranergene obadenovec utilizes VBL’s proprietary Vascular Targeting System (VTS) to target the tumor vasculature for cancer therapy. Unlike anti-VEGF or TKIs, ofranergene obadenovec does not aim to block a specific pro-angiogenic pathway; instead, it uses an angiogenesis-specific sensor (VBL’s PPE-1-3x proprietary promoter) to specifically induce cell death in angiogenic endothelial cells in the tumor milieu. This mechanism retains activity regardless of baseline tumor mutations or the identity of the pro-angiogenic factors secreted by the tumor and shows efficacy even after failure of prior treatment with other anti-angiogenics. Moreover, ofranergene obadenovec induces specific anti-tumor immune response, which is accompanied by recruitment of CD8 T-cells and apoptosis of tumor cells. Ofranergene obadenovec completed a Phase II study in rGBM, which showed a statistically significant improvement in overall survival in patients treated with ofranergene obadenovec through progression, compared to either patients treated with ofranergene obadenovec followed by bevacizumab alone, or to historical bevacizumab data.

Scope of the report

The report provides insights into:

  • A comprehensive product overview including the product description, mechanism of action, dosage and administration, Research and Development activity.
  • Elaborated details on regulatory milestones and other development activities have been provided in this report.
  • The report also highlights the drug research and development activity details across the United States, Europe and Japan.
  • The report also covers the patents information with expiry timeline around VB 111 (VBL Therapeutics).
  • The report contains forecasted sales for VB 111 (VBL Therapeutics) till 2030.
  • Comprehensive coverage of the late-stage emerging therapies (Phase III) for Glioblastoma.
  • The report also features the SWOT analysis with analyst insights and key findings of VB 111 (VBL Therapeutics).


The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

VB 111 (VBL Therapeutics) Analytical Perspective by DelveInsight

  • In-depth VB 111 (VBL Therapeutics) Market Assessment

This report provides a detailed market assessment of VB 111 (VBL Therapeutics) in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2020 to 2030.

  • VB 111 (VBL Therapeutics) Clinical Assessment

The report provides the clinical trials information of VB 111 (VBL Therapeutics) covering trial interventions, trial conditions, trial status, start and completion dates.

Report highlights  

  • In the coming years, the market scenario for Glioblastoma is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.   
  • The companies and academics are working to assess challenges and seek opportunities that could influence VB 111 (VBL Therapeutics) dominance. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Other emerging products for Glioblastoma are giving market competition to VB 111 (VBL Therapeutics) and launch of late-stage emerging therapies in the near future will significantly impact the market.  
  • A detailed description of regulatory milestones, development activities, and some key findings provide the current development scenario of VB 111 (VBL Therapeutics).
  • Our in-depth analysis of the forecasted sales data of VB 111 (VBL Therapeutics) from 2020 to 2030 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the VB 111 (VBL Therapeutics). 

Key Questions

  • Which company is developing VB 111 (VBL Therapeutics) along with the phase of the clinical study?
  • What is the technology utilized in the development of VB 111 (VBL Therapeutics)?
  • What is the product type, route of administration and mechanism of action of VB 111 (VBL Therapeutics)?
  • What is the clinical trial status of the study and study completion date?
  • What are the key collaborations, mergers and acquisitions, licensing and other activities related to the VB 111 (VBL Therapeutics) development?
  • What are the key designations that have been granted to VB 111 (VBL Therapeutics)?
  • What is the forecasted market scenario of VB 111 (VBL Therapeutics)?
  • What is the history of VB 111 (VBL Therapeutics) and what is its future?
  • What is the forecasted sales of VB 111 (VBL Therapeutics) in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?  
  • What are the other emerging products available and how these are giving competition to VB 111 (VBL Therapeutics)?
  • Which are the late-stage emerging therapies under development for the treatment of the PPD?


1. Drug Overview

1.1. Product Detail

1.2. Mechanism of Action

1.3. Dosage and Administration

1.4. Research and development activity

1.4.1. Clinical Development

1.4.2. Safety and Efficacy

1.5. Other Development Activities

2. Market Assesment

2.1. 7MM Market Analysis

2.2. The United States Market

2.3. Germany Market

2.4. France Market

2.5. Italy Market

2.6. Spain Market

2.7. United Kingdom Market

2.8. Japan Market

3. SWOT Analysis

4. Analyst Views

5. Market Competitors

6. Other Emerging Therapies

7. Appendix

8. Report Purchase Options

List of Tables

Table 1 VB 111 (VBL THERAPEUTICS), Description

Table 2 VB 111 (VBL THERAPEUTICS), Clinical Trial Description

Table 3 VB 111 (VBL THERAPEUTICS), 7MM Market Size from 2020 to 2030 (in Million USD)

Table 4 Market Competitors

Table 5 Other Emerging Therapies

List of Figures

Figure 1 The Development Timeline of VB 111 (VBL THERAPEUTICS)

Figure 2 Patent Details, VB 111 (VBL THERAPEUTICS)

Figure 3 VB 111 (VBL THERAPEUTICS), 7MM Market Size from 2020 to 2030 (in Million USD)

Figure 4 VB 111 (VBL THERAPEUTICS), US Market Size from 2020 to 2030 (in Millions USD)

Figure 5 VB 111 (VBL THERAPEUTICS), EU5 Market Size from 2020 to 2030 (in Millions USD)

Figure 6 VB 111 (VBL THERAPEUTICS), Japan Market Size from 2020 to 2030 (in Millions USD)

  • Tags:
  • VB 111 (VBL Therapeutics)
  • VB 111 (VBL Therapeutics) Marketed...
  • VB 111 (VBL Therapeutics) Market A...
  • VB 111 (VBL Therapeutics) API Manu...
  • VB 111 (VBL Therapeutics) US DMF

Forward to Friend

Need A Quote